NCT01180153Unknown2 期
An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- objective response rate
研究概览
简要总结
To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.
详细描述
To list in cases with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma that have not been treated before,confirm the efficacy and safety of combined S-1/L-OHP regimen for the biliary tract or ampullary carcinoma, providing evidence-based proof for the future treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent has been signed by the subject itself;
- •Aged over 18;
- •With a definite pathological or cytological diagnosis of adenocarcinoma;
- •No pre-treatment (including radiotherapy, chemotherapy, immunotherapy, etc.). For recurrent cases, if the subjects have received adjuvant chemotherapy without S-1 or L-OHP after surgery and the time to the end date of adjuvant chemotherapy is over 6 months, they can also be enrolled;
- •Enhanced helical CT or MRI scanning shows a target lesion over 1cm within 14 days before enrollment
- •Within 7 days before enrollment, baseline blood routine and biochemical indicators meet the following criteria:
- •Hemoglobin ≥ 90g/L,
- •Absolute neutrophil count (ANC) ≥ 1.5 × 109/L,
- •Platelets ≥ 100×109/L，
- •Serum total bilirubin < 1.5 times of the upper normal limit,
- •Serum creatinine < upper limit of normal,
- •Serum albumin ≥ 30 g/L;
- •Can receive oral administration;
- •Karnofsky(KPS) score ≥ 70 points;
- •Expected survival time is more than 90 days;
- •Women of childbearing age must receive urine or blood pregnancy test within 7 days before randomization and the results are negative;
- •Male and female patients of appropriate reproductive age are willing to use reliable contraception methods for contraception in the process of study till 30 days after drug withdrawal.
排除标准
- •Patients with a severe drug allergy history (including mildly allergic to L-OHP, 5-FU, FT207, 5-HT3 receptor antagonist);
- •Patients who participated or are participating in other clinical trials within 4 weeks before enrollment;
- •Patients who have received blood transfusion, blood products and hematopoietic factor preparations such as G-CSF within 15 days before enrollment;
- •Patients who have undergone a surgery within 15 days before enrollment, and its effects have not been eliminated;
- •Patients with diarrhea;
- •Patients with a complication of active infection (infection causes a fever above 38 ℃);
- •Patients accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding and perforation, etc. that cause difficulty in taking S-1 orally;
- •Patients with severe liver disease (e.g. active hepatitis, cirrhosis, etc.), renal insufficiency, severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.), or uncontrollable diabetes, hypertension and other chronic systemic diseases;
- •Patients who have received long-term systemic steroid therapy (Note: short-term users with steroid withdrawal > 2 weeks can be selected);
- •Patients with brain metastases or suspected of brain metastases;
- •Patients with peripheral nervous system disorder or a history of significant mental disorder and central nervous system disorder;
- •Heart disease of significant clinical symptoms, e.g. congestive heart failure, coronary heart disease with significant symptoms, arrhythmia and hypertension that are difficult to be controlled by drugs, or with an episode of myocardial infarction within 6 months, or cardiac insufficiency;
- •Patients with pleural effusion, ascites, or pericardial effusion that needs drainage;
- •Pregnant or breast-feeding women, or male and female patients of appropriate reproductive age who refuse to take contraceptive measures;
- •Patients who have suffered from other malignancies within 5 years, except basal cell carcinoma and carcinoma in situ of uterine cervix that have already been cured;
- •Patients without legal capability, or who can not continue the study due to medical or ethical reasons;
- •Patients who are determined not suitable to participate in this clinical trial by the investigators.
研究组 & 干预措施
SOX: advanced BTC or ampullary carcinoma
Experimental
unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
干预措施: S-1 oxaliplatin (Drug)
结局指标
主要结局
objective response rate
时间窗: 2 years
to evaluate objective response rate (ORR) of SOX regimen to BTC (Ampullary Adenocarcinoma)
次要结局
- overall survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant SettingRectal CarcinomaNCT01227239Japan Clinical Cancer Research Organization45
Unknown
1 期
SOX as Adjuvant Chemotherapy for Resectable Gastric CancerGastric CancerNCT01542294Chinese Academy of Medical Sciences71
已完成
2 期
Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast CancerBreast NeoplasmsNCT00527930Seoul National University Hospital87
终止
3 期
Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerGastric CancerNCT02867839Peking University Cancer Hospital & Institute29
已完成
2 期
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric CancerStomach NeoplasmsNCT01531452Chinese Academy of Medical Sciences43